- Home
- NEA vs RARE Comparison
NEA vs RARE Comparison
Compare NEA & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEA
- RARE
- Stock Information
- Founded
- NEA 2002
- RARE 2010
- Country
- NEA United States
- RARE United States
- Employees
- NEA N/A
- RARE N/A
- Industry
- NEA Finance/Investors Services
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- NEA Finance
- RARE Health Care
- Exchange
- NEA Nasdaq
- RARE Nasdaq
- Market Cap
- NEA 3.3B
- RARE 3.5B
- IPO Year
- NEA N/A
- RARE 2014
- Fundamental
- Price
- NEA $10.94
- RARE $29.31
- Analyst Decision
- NEA
- RARE Strong Buy
- Analyst Count
- NEA 0
- RARE 15
- Target Price
- NEA N/A
- RARE $89.00
- AVG Volume (30 Days)
- NEA 803.4K
- RARE 1.9M
- Earning Date
- NEA 01-01-0001
- RARE 07-31-2025
- Dividend Yield
- NEA 4.23%
- RARE N/A
- EPS Growth
- NEA N/A
- RARE N/A
- EPS
- NEA N/A
- RARE N/A
- Revenue
- NEA N/A
- RARE $590,689,000.00
- Revenue This Year
- NEA N/A
- RARE $18.94
- Revenue Next Year
- NEA N/A
- RARE $28.93
- P/E Ratio
- NEA N/A
- RARE N/A
- Revenue Growth
- NEA N/A
- RARE 33.46
- 52 Week Low
- NEA $9.20
- RARE $29.06
- 52 Week High
- NEA $11.37
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- NEA 53.97
- RARE 31.08
- Support Level
- NEA $10.79
- RARE $29.06
- Resistance Level
- NEA $11.04
- RARE $42.37
- Average True Range (ATR)
- NEA 0.05
- RARE 1.79
- MACD
- NEA 0.01
- RARE -0.70
- Stochastic Oscillator
- NEA 64.29
- RARE 5.07
About NEA Nuveen AMT-Free Quality Municipal Income Fund of Beneficial Interest Par Value $.01
Nuveen AMT-Free Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax and the alternative minimum tax applicable to individuals, by investing in an actively managed portfolio of tax-exempt municipal securities. The company invest in Transportation, Utilities, Healthcare, Education and Civics, and other sectors, with maximum investment in Transportation.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.